Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Asian Biomedicine
Volume 16 (2022): Numero 2 (April 2022)
Accesso libero
Atorvastatin reduces alloxan-induced impairment of aversive stimulus memory in mice
Osman Kukula
Osman Kukula
e
Caner Günaydın
Caner Günaydın
| 29 apr 2022
Asian Biomedicine
Volume 16 (2022): Numero 2 (April 2022)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Original article
Pubblicato online:
29 apr 2022
Pagine:
71 - 78
DOI:
https://doi.org/10.2478/abm-2022-0009
Parole chiave
alloxan
,
atorvastatin
,
avoidance learning
,
diabetes mellitus
,
experimental
,
memory
© 2022 Osman Kukula et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Figure 1
(A) Mouse weight throughout the experiment analyzed with a general linearized model. #P < 0.05, ###P < 0.001 alloxan-induced diabetes vs. vehicle control. ***P < 0.001 liraglutide + alloxan-induced diabetes vs. alloxan-induced diabetes. (B) Blood glucose levels after oral glucose administration for each experimental group in the OGTT. (C) Locomotor activity for each experimental group. Statistical analyses were conducted using a one-way ANOVA with a Tukey post hoc test. Data are represented as mean ± standard deviation. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus; OGTT, oral glucose tolerance test.
Figure 2
Effect of each drug treatment on (A) initial latency and (B) retention period latency in the passive avoidance test. There were no significant differences in initial latency between experimental groups. Alloxan-induced diabetes significantly decreased retention period latency. #P < 0.05 vs. vehicle control. Atorvastatin significantly attenuated the alloxan-induced diabetes decrease in retention period latency. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide also significantly attenuated the alloxan-induced diabetes decrease in retention period latency even more than atorvastatin. ***P < 0.001. Symbols represent each data point and the bar indicates mean ± standard deviation. Statistical analyses were performed using a Kruskal–Wallis test. Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Figure 3
The amount of time spent in the dark compartment by mice in each experimental group. Alloxan-induced diabetes significantly increased the time spent in the dark compartment. #P < 0.05 vs. saline vehicle control. Atorvastatin attenuated this increase in mice with alloxan-induced diabetes. *P < 0.05 vs. alloxan-induced diabetes; +P < 0.05 vs. alloxan-induced diabetes + liraglutide. Liraglutide significantly attenuated the time mice with alloxan-induced diabetes spent in the dark compartment. ***P < 0.001 vs. alloxan-induced diabetes. Symbols represent each data point and the bars indicate mean ± standard deviation. Statistical analyses were performed using a one-way ANOVA with a Tukey post hoc test. ANOVA, analysis of variance; Ator, atorvastatin; Control, saline vehicle treatment alone as a negative control; DM, alloxan-induced model of diabetes mellitus.
Anteprima